UCLA's California NanoSystems Institute partners with Abraxis BioScience

July 26, 2007

The California NanoSystems Institute (CNSI) at UCLA today announced a partnership with the integrated global biopharmaceutical company Abraxis BioScience Inc. to collaborate on nanobiotechnology research for the advancement of new technologies in medicine.

Abraxis BioScience will collaborate with the institute and its team of leading researchers to capitalize on the recent explosion in nanoscience and to chart the future of nanotechnology within biotechnology. Abraxis has agreed to contribute $10 million over 10 years to fund collaborative projects at UCLA's new CNSI building. The Abraxis/CNSI Research Collaboration Lab will focus on translational science, quickly translating scientific discoveries into practical applications.

Abraxis BioScience has joined the CNSI Partners Program and is the institute's first partner in the area of pharmaceuticals and biotechnology. The partnership provides CNSI and Abraxis researchers the opportunity to jointly pursue innovative approaches to the diagnosis and treatment of life threatening diseases, leveraging the complementary resources and skills of both organizations. To further support the partnership, visiting scholars from other institutions will also participate in the collaborative research programs.

"We are eager to collaborate with Abraxis BioScience. Cross-disciplinary collaboration is vital to our research efforts," said Fraser Stoddart, CNSI director and UCLA's Fred Kavli Professor of Nanosystems Sciences. "The exciting thing about nanosystems research is that it is bringing about a sea change in the academic environment -- it is breaking down the barriers between disciplines to achieve a seamless integration between chemistry, physics, biology and engineering in all of their different forms."

"We are very excited about this research collaboration with the CNSI and believe this type of relationship emphasizes our commitment toward pursuing innovative research and forging new paradigms of drug discovery and personalized drug development," said Dr. Patrick Soon-Shiong, chairman and chief executive officer of Abraxis BioScience. "This relationship allows both organizations to gain access to important research that may have the potential to change the way diseases are treated."

"Abraxis has an established history of developing innovative technology," said Dr. Leonard H. Rome, CNSI associate director and senior associate dean for research at the David Geffen School of Medicine at UCLA. "We are confident they will be a strong and committed partner in furthering important research and the development of drugs to treat life-threatening and debilitating illnesses."
-end-
About Abraxis BioScience Inc.

Abraxis BioScience Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology, such as its proprietary nab (nanoparticle albumin-bound) platform, to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. Abraxane, the first product approved by the Food and Drug Administration to use the nab platform, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.

About the California Nanosystems Institute

The CNSI is a multidisciplinary research center at UCLA whose mission is to encourage university-industry collaboration and to enable the rapid commercialization of discoveries in nanosystems. CNSI members include some of the world's preeminent scientists, and the work conducted at the institute represents world-class expertise in five targeted areas of nanosystems-related research: renewable energy; environmental nanotechnology and nanotoxicology; nanobiotechnology and biomaterials; nanomechanical and nanofluidic systems; and nanoelectronics, photonics and architectonics. For additional information on the institute, visit www.cnsi.ucla.edu.

University of California - Los Angeles

Related Biotechnology Articles from Brightsurf:

Cyanobacteria as "green" catalysts in biotechnology
Researchers from TU Graz and Ruhr University Bochum show in the journal ACS Catalysis how the catalytic activity of cyanobacteria, also known as blue-green algae, can be significantly increased.

Biotechnology to the rescue of Brussels sprouts
An international team has identified the genes that make these plants resistant to the pathogen that attacks crops belonging to the cabbage family all over the world.

UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.

Faster genome evolution methods to transform yeast for industrial biotechnology
A research team led by Prof. DAI Junbiao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, in collaboration with Prof.

New innovations in cell-free biotechnology
Professor Michael Jewett's new platform to conduct cell-free protein synthesis could lead to improved quality of manufactured protein therapeutics and biomaterials.

Silk 'micrococoons' could be used in biotechnology and medicine
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.

The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.

Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.

China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.

Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.

Read More: Biotechnology News and Biotechnology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.